Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxprenolol
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Actimed Therapeutics Granted FDA Orphan Drug Status for ALS Treatment ACM-002
Details : ACM-002 (S-oxprenolol) has demonstrated slowing disease progression, improvement in survival, attenuation of muscle loss, motor neuron protection in amyotrophic lateral sclerosis (ALS).
Brand Name : ACM-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 04, 2024
Lead Product(s) : Oxprenolol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oxprenolol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Faraday Pharmaceuticals
Deal Size : $134.7 million
Deal Type : Licensing Agreement
Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol
Details : Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS).
Brand Name : ACM-002
Molecule Type : Small molecule
Upfront Cash : $2.7 million
April 13, 2021
Lead Product(s) : Oxprenolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Faraday Pharmaceuticals
Deal Size : $134.7 million
Deal Type : Licensing Agreement
Lead Product(s) : Oxprenolol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ACM-002 (S-oxprenolol) is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. The new patent contains claims which cover the treatment of the symptoms of cachexia in patients having a late stage cance...
Brand Name : ACM-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2020
Lead Product(s) : Oxprenolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oxprenolol
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Actimed Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Actimed Therapeutics has licensed additional European patent rights to S-oxprenolol in amyotrophic lateral sclerosis (ALS) from Charité – Universitätsmedizin Berlin (Charité). This gives Actimed global rights in this indication.
Brand Name : ACM-002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : Oxprenolol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Actimed Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?